Explore /
Poster
/ Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.

Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.

Authors

Thomas H. Cartwright

Ocala Oncology, Ocala, FL

Thomas H. Cartwright , Marwan Fakih , Pilar Garcia-Alfonso , Zdenĕk Linke , Ana Ruíz Casado , Eduardo Polo Marques , Pascaline Picard , Marina Celanovic , Arvind Rup Singh , Taylor Salinardi , Ian Chau

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

ENCEPP/SDPP/4836

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 212)

Abstract #

212

Poster Bd #

K12

Abstract Disclosures

Similar Posters

Poster

2015 Gastrointestinal Cancers Symposium

$Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC).$

Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).

First Author: Timothy Jay Price

Poster

2024 ASCO Gastrointestinal Cancers Symposium

$HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.$